Company intelligence / Profile preview

Cerevel Therapeutics

Cambridge, Massachusetts, United Statescerevel.gcs-web.com ↗

Ownership: Public · CERE
Employees: ~355
Development stage: Phase 3

Overview

Cerevel's lead candidate tavapadon met its primary endpoint in a Phase III TEMPO-3 trial for Parkinson's disease, showing significant improvement in symptom control. Emraclidine, their schizophrenia drug, is completing Phase II trials. The company was acquired by AbbVie in August 2024.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesreceptor modulators
Industry: Biotech

Drug pipeline

4 assets

emraclidine

Phase 2

Indications: Schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis

3 more assets in the full pipeline.

Request access →

Partnerships

PfizerBain Capital

Financials

Market cap: $8.2B
Total revenue: $0
Enterprise value: $7.7B

Beyond the preview

Go deeper on Cerevel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerevel Therapeutics.

Explore the full profile